Published on 21/12/2025
How a Rare Pediatric Trial Achieved Rapid Recruitment: A Real-World Case Study
Background: The Challenge of Recruiting in Rare Pediatric Disorders
Recruiting pediatric patients for rare disease trials is among the most complex tasks in clinical research. The small population size, strict eligibility criteria, and logistical and ethical considerations make it difficult to meet enrollment targets. When the condition is ultra-rare and affects children, the challenges multiply—requiring innovative, patient-centric approaches that prioritize caregivers, regulatory compliance, and feasibility.
This case study explores the recruitment strategies and outcomes of a recent Phase II trial for Congenital Hyperinsulinism (CHI), a rare genetic disorder affecting approximately 1 in 50,000 children globally. The disorder leads to dangerously low blood sugar levels in infants and young children and requires urgent intervention to prevent neurological damage.
Trial Design and Recruitment Objectives
The sponsor—a mid-sized biotech company—initiated a multi-country Phase II clinical trial of an oral investigational agent targeting KATP-channel mutations common in CHI. The trial targeted 20 pediatric patients, aged 6 months to 10 years, across five countries (USA, UK, India, Poland, and Brazil).
Primary recruitment goals:
- Enroll 20 qualified pediatric participants in 6 months
- Ensure diversity across genetic backgrounds and geographies
- Minimize site burden
Challenges identified included limited public awareness, diagnostic delays, logistical constraints for travel, and ethical concerns around informed consent and pediatric assent.
Pre-Recruitment Preparation and Site Selection
The sponsor adopted a proactive recruitment strategy, beginning with extensive feasibility assessments and pre-screening through pediatric endocrinology clinics and genetic counseling centers. Criteria for site selection included:
- Prior experience with pediatric rare disease trials
- Availability of genetic testing for ABCC8 and KCNJ11 mutations
- Established relationships with patient advocacy groups
- Infrastructure to support remote visit models
Five trial sites were selected across four continents, each trained in protocol delivery, eConsent tools, and pediatric engagement techniques. Site-specific modifications were approved by local IRBs to address regional nuances in caregiver involvement and data privacy regulations.
Engaging Advocacy Groups and Registries
Collaboration with advocacy groups played a vital role in generating trial awareness. The sponsor partnered with Congenital Hyperinsulinism International (CHI International) and Rare Kids Global to:
- Distribute IRB-approved recruitment materials in newsletters and websites
- Host webinars with principal investigators for caregivers
- Send pre-screening questionnaires to registry members with opt-in consent
These efforts resulted in over 180 interested caregivers responding within the first 30 days of the campaign. 44 met initial eligibility based on age, diagnosis, and treatment history.
Implementing Remote and Hybrid Trial Models
To reduce site visits and improve participation among families with young children, the sponsor implemented a hybrid model with decentralized components:
- Home nurse visits for blood glucose monitoring and sample collection
- Telemedicine appointments for physician assessments and dosing instructions
- Direct-to-patient investigational product shipments with nurse support
Outcomes from this model included:
- 85% of study visits conducted remotely
- Only two site visits required: screening and final assessment
- Zero missed visits or dose interruptions
Such flexibility was especially impactful for participants in remote areas of Brazil and rural India, where travel was previously a barrier to participation.
Ethical and Regulatory Considerations in Pediatric Enrollment
Given the age group, additional safeguards were built into the informed consent and assent processes. These included:
- Caregiver-facing video modules explaining trial expectations
- Child assent forms with visuals and simplified language for children aged 7+
- Local translations of all study materials, reviewed by cultural liaisons
Example Consent Tool Snapshot:
| Document | Audience | Language |
|---|---|---|
| Guardian Consent Form | Parent/Caregiver | English, Portuguese, Hindi |
| Assent Form (7-10 yrs) | Child Participant | English, Polish |
These tailored approaches helped ensure full comprehension and voluntary participation, satisfying IRB and GCP expectations.
Recruitment Outcomes and Key Metrics
The recruitment phase was completed in just 4.5 months—6 weeks ahead of schedule. Key results:
- 20 participants enrolled from 5 countries
- Zero withdrawals during the treatment phase
- Average caregiver satisfaction rating: 9.4/10
- No major protocol deviations or ethics queries raised
Feedback from sites indicated that the hybrid model and advocacy support were central to this success. Caregivers appreciated the ability to stay home, while maintaining access to a well-coordinated care team and trial support services.
Lessons Learned and Future Applications
This trial underscores the importance of planning, flexibility, and caregiver engagement in rare pediatric recruitment. Key takeaways for future studies:
- Start community engagement early—months before site initiation
- Partner with both global and local advocacy organizations
- Design study protocols with remote data collection options from the outset
- Respect cultural and linguistic diversity in materials and communication
- Empower caregivers with support tools, FAQs, and transparency
The sponsor has since expanded this recruitment model to other pediatric rare diseases, including Leigh Syndrome and Smith-Lemli-Opitz Syndrome, with similarly promising outcomes.
Conclusion: Proving That Pediatric Rare Trial Recruitment Can Succeed
Recruitment in pediatric rare disease trials may seem daunting, but with the right strategies—centered on flexibility, advocacy, ethics, and digital tools—success is not only possible but scalable. This case study demonstrates that when sponsors meet families where they are, and build trials around their needs, recruitment becomes not just faster, but more humane, inclusive, and effective.